Core Viewpoint - The company, Baike Biotech (688276.SH), has received the Drug Registration Certificate for a nasal spray live attenuated influenza vaccine from the National Medical Products Administration, marking a significant advancement in its product offerings [1] Group 1: Product Development - The newly approved nasal spray influenza vaccine simulates natural infection by the influenza virus, establishing an immune barrier in the respiratory tract to prevent viral invasion [1] - This vaccine is an upgraded liquid formulation from the previously available freeze-dried version, eliminating the need for reconstitution during use, thus enhancing convenience for administration [1] - The target population for this vaccine includes individuals aged 3 to 17 years [1]

Group 1 - The core point of the article is that Baike Biological has received approval for its nasal spray influenza live attenuated vaccine from the National Medical Products Administration [1] - The vaccine is classified as a preventive biological product and is intended for the age group of 3 to 17 years [1] - The vaccine is in a nasal formulation with a specification of 0.2ml per dose [1]

Core Viewpoint - The company has received the drug registration certificate for the nasal spray influenza live attenuated vaccine from the National Medical Products Administration, which is expected to enhance the promotion and use of its influenza vaccine products [1] Group 1: Product Development - The vaccine is suitable for individuals aged 3 to 17 years and is administered via the nasal route, creating an initial immune barrier against influenza virus invasion in the respiratory tract [1] - The vaccine formulation has been upgraded from a freeze-dried form to a liquid form, making it more convenient for use [1] Group 2: Market Impact - The approval of this vaccine is anticipated to optimize the company's product structure and strengthen its core competitiveness in the market [1] - There is uncertainty regarding the timeline for the vaccine's market launch and sales, which presents potential investment risks [1]

证券代码：688276 证券简称：百克生物 公告编号：2025-027 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 9 月 1 日（星期一）上午 09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 25 日（星期一）至 8 月 29 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bchtpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 长春百克生物科技股份公司（以下简称"公司"）将于 2025 年 8 月 30 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 9 月 1 日（星期一）上午 09:00-10:0 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688276 | 百克生物 | 25.40 | 8.09% | 11.19万 | 2.75亿 | | 688520 | 神州细胞 | 73.20 | 6.94% | 15.40万 | 11.00亿 | | 688331 | 荣昌生物 | 76.99 | 4.35% | - 14.02万 | 10.53亿 | | 300239 | 东宝生物 | 5.94 | 3.85% | 19.94万 | 1.17亿 | | 688163 | 赛伦生物 | 26.15 | 3.81% | 2.75万 | 7126.14万 | | 300841 | 康华生物 | 92.06 | 3.67% | 6.31万 | 5.74亿 | | 301166 | 优宁维 | 33.75 | 2.99% | 1.91万 | 6363.30万 | | 688177 | 百圆泰 | 33.29 | 2.91% | 4.75万 | 1.56亿 | | 600739 | 辽宁成大 | + 1 ...

Market Overview - The Shanghai Composite Index closed at 3696.77 points, above the annual line, with an increase of 0.83% [1] - The total trading volume of A-shares reached 22,728.38 billion yuan [1] Stocks Breaking Annual Line - A total of 97 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Mingyang Electric: 8.12% deviation, closing price at 43.45 yuan, with a daily increase of 14.49% and turnover rate of 11.79% [1] - Baike Biological: 6.78% deviation, closing price at 25.40 yuan, with a daily increase of 8.09% and turnover rate of 2.70% [1] - ST Lianchuang: 5.16% deviation, closing price at 5.49 yuan, with a daily increase of 5.78% and turnover rate of 3.46% [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the annual line with smaller deviation rates include: - Times Electric: 3.99% deviation, closing price at 4.01 yuan, with a daily increase of 4.16% and turnover rate of 1.11% [1] - Xinda Real Estate: 3.99% deviation, closing price at 39.82 yuan, with a daily increase of 8.35% and turnover rate of 5.62% [1] - China National Materials: 3.76% deviation, closing price at 9.01 yuan, with a daily increase of 4.16% and turnover rate of 3.74% [1]

金融界消息 截至2025年8月14日收盘，百克生物（688276）报收于23.5元，下跌2.65%，换手率1.29%， 成交量5.32万手，成交金额1.27亿元。 天眼查商业履历信息显示，长春百克生物科技股份公司，成立于2004年，位于长春市，是一家以从事医 药制造业为主的企业。企业注册资本41365.7598万人民币，实缴资本36010万人民币。公司法定代表人 为李秀峰。 通过天眼查大数据分析，长春百克生物科技股份公司共对外投资了7家企业，参与招投标项目1039次， 知识产权方面有商标信息33条，专利信息69条，此外企业还拥有行政许可133个。 来源：金融界 资金流向方面，今日主力资金净流出2938.88万元，占比成交额23.18%。其中，超大单净流出2261.76万 元、占成交额17.84%，大单净流出677.12万元、占成交额5.34%，中单净流出流入2129.91万元、占成交 额16.8%，小单净流入808.96万元、占成交额6.38%。 百克生物最新一期业绩显示，截至2025一季报，公司营业总收入1.62亿元、同比减少39.96%，归属净利 润106.43万元，同比减少98.24%，扣非净利润341 ...

| 002356 | 赫美集 | 1.26 | 1.76 | 3.20 | 3.22 | 0.72 | | --- | --- | --- | --- | --- | --- | --- | | | 团 | | | | | | | 002813 | 路畅科 | 1.45 | 4.69 | 24.37 | 24.54 | 0.72 | | | 技 | | | | | | | 002150 | 通润装 | 1.54 | 3.86 | 12.47 | 12.55 | 0.64 | | | 备 | | | | | | | 002332 | 仙琚制 | 1.07 | 2.85 | 10.34 | 10.41 | 0.64 | | | 药 | | | | | | | 000875 | 吉电股 | 1.74 | 1.57 | 5.24 | 5.27 | 0.63 | | | 份 | | | | | | | 688276 | 百克生 | 2.69 | 1.71 | 23.88 | 24.03 | 0.61 | | | 物 | | | | | | | 601158 | 重庆水 | 0.64 | 0.20 | 4.70 | 4. ...

| 601139 | 深圳燃 | 0.92 | 0.30 | 6.57 | 6.61 | 0.63 | | --- | --- | --- | --- | --- | --- | --- | | | 气 | | | | | | | 002813 | 路畅科 | 1.36 | 2.69 | 24.37 | 24.52 | 0.63 | | | 技 | | | | | | | 000966 | 长源电 | 0.66 | 0.71 | 4.58 | 4.60 | 0.45 | | | 力 | | | | | | | 601158 | 重庆水 | 0.43 | 0.12 | 4.70 | 4.72 | 0.35 | | | 务 | | | | | | | 000875 | 吉电股 | 1.35 | 0.84 | 5.24 | 5.25 | 0.25 | | | 份 | | | | | | | 002032 | 苏泊尔 | 0.21 | 0.08 | 51.32 | 51.39 | 0.14 | | 002157 | 正邦科 | 0.70 | 0.38 | 2.87 | 2.87 | 0.12 | | | 技 | | ...

证券代码：688276 证券简称：百克生物 公告编号：2025-026 经与会监事审议表决，一致通过如下议案： （一）审议通过《关于归还前次用于临时补充流动资金的募集资金暨使用 部分闲置募集资金临时补充流动资金的议案》 监事会认为：本次使用部分闲置募集资金临时补充流动资金系用于与主营业 务相关的生产经营，不会通过直接或者间接安排用于新股配售、申购，或者用于 股票及其衍生品种、可转换公司债券等的交易；不影响募集资金投资项目的正常 实施，亦不存在变相改变募集资金投向和损害中小股东利益的情形。综上，公司 监事会同意公司本次使用金额不超过人民币 10,000 万元的闲置募集资金临时补 充流动资金。 表决情况：同意 3 票，弃权 0 票，反对 0 票。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《长春百克生物科技股份公司关于归还前次用于临时补充流动资金的募集资金 暨使用部分闲置募集资金临时补充流动资金的公告》（公告编号：2025-025）。 长春百克生物科技股份公司 第六届监事会第三次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏 ...